

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Resonance Health Limited
ABN 96 006 762 92

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Travis Baroni
Date of last notice	28 November 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect Interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Direct interest – Travis Baroni
Date of change	09 March 2021
No. of securities held prior to change	Direct - 500,000 shares 1,000,000 Unlisted Options exercisable at \$0.15 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.175 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.20 expiring 28 November 2022
Class	Fully paid ordinary shares and Unlisted Options
Number acquired	Nil

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number disposed	<p>Direct – 282,500 fully paid ordinary shares</p> <p>400,000 Unlisted Options exercisable at \$0.15 expiring 28 November 2022</p> <p>400,000 Unlisted Options exercisable at \$0.175 expiring 28 November 2022</p> <p>400,000 Unlisted Options exercisable at \$0.20 expiring 28 November 2022</p>
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>Nil. Share were split between Dr Baroni and his wife as a result of settlement agreement approved by the Family Court.</p>
No. of securities held after change	<p>Direct – 217,500 shares</p> <p>600,000 Unlisted Options exercisable at \$0.15 expiring 28 November 2022</p> <p>600,000 Unlisted Options exercisable at \$0.175 expiring 28 November 2022</p> <p>600,000 Unlisted Options exercisable at \$0.20 expiring 28 November 2022</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<p>Off market transfer of 282,500 fully paid ordinary shares and 1.2 million unlisted options at various exercise prices. Shares and unlisted options are now held in a new entity that Dr Travis Baroni has no involvement with.</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.